Time-to-failure in 1st-line endocrine therapy with ER+/HER2-metastatic breast cancer

被引：0
|
作者：
Nishimura, S. [1 ]
Akiyoshi, S. [1 ]
Koga, C. [1 ]
Oikawa, M. [1 ]
Nskamura, Y. [1 ]
Ishida, M. [1 ]
Ohno, S. [1 ]
机构：
[1] Kyushu Natl Canc Ctr, Breast Oncol, Fukuoka, Japan
来源：
BREAST | 2015年 / 24卷
关键词：
D O I：
10.1016/S0960-9776(15)70209-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P168
引用
收藏
页码：S82 / S83
页数：2
相关论文
共 50 条
  • [21] VAGINAL/VULVAR SYMPTOMS WITH LASOFOXIFENE VERSUS FULVESTRANT IN ESR1-MUTATED, ER+/HER2-METASTATIC BREAST CANCER PATIENTS
    Goldfarb, S. B.
    Sammons, S. L.
    Meisel, J. L.
    Pluard, T. J.
    Jenkins, S. N.
    Komm, B.
    Carroll, D.
    Portman, D. J.
    JOURNAL OF SEXUAL MEDICINE, 2023, 20
  • [22] Plasma thymidine kinase 1 activity and outcome of ER+ HER2− metastatic breast cancer patients treated with palbociclib and endocrine therapy
    Luc Cabel
    Dan Rosenblum
    Florence Lerebours
    Etienne Brain
    Delphine Loirat
    Mattias Bergqvist
    Paul Cottu
    Anne Donnadieu
    Anne Bethune
    Nicolas Kiavue
    Manuel Rodrigues
    Jean-Yves Pierga
    Marie-Laure Tanguy
    François-Clément Bidard
    Breast Cancer Research, 22
  • [23] Open-label phase II study of everolimus plus endocrine therapy in post-menopausal women with ER+, HER2-metastatic breast cancer (Chloe trial)
    Shien, T.
    Shimomura, A.
    Uemura, Y.
    Kato, H.
    Kitada, M.
    Kikawa, Y.
    Shiba, E.
    Yoshida, T.
    Morimoto, T.
    Toyama, T.
    Aihara, T.
    Mukai, H.
    ANNALS OF ONCOLOGY, 2017, 28
  • [24] PYTHIA: A phase II study of palbociclib plus fulvestrant for pretreated patients with ER+/HER2-metastatic breast cancer
    Zardavas, D.
    Regan, M.
    Maibach, R.
    Ruepp, B.
    Hiltbrunner, A.
    Blacher, L.
    Gelber, R.
    Gebhart, G.
    Di Leo, A.
    Hilbers, F.
    Colleoni, M.
    Zoppoli, G.
    Bertelli, G.
    Bliss, J.
    Duhoux, F.
    Piccart, M.
    Malorni, L.
    ANNALS OF ONCOLOGY, 2017, 28
  • [25] Targeted therapies for ER+/HER2- metastatic breast cancer
    Mutsuko Yamamoto-Ibusuki
    Monica Arnedos
    Fabrice André
    BMC Medicine, 13
  • [26] EFFICACY AND SAFETY PROFILE OF PALBOCICLIB AND FULVESTRANT IN PATIENTS ER+/HER2-METASTATIC BREAST CANCER OF A SINGLE ONCOLOGICAL CENTRE
    Alevizopoulos, Nektarios
    Alexandris, Dimitrios
    Folinas, Konstantinos
    Dimitriadou, Areti
    Pavlakis, Michael
    Kammenou, Helen
    BREAST, 2021, 59 : S63 - S63
  • [27] 1ST-LINE AND SALVAGE THERAPY OF METASTATIC BREAST-CANCER WITH MITOMYCIN VINBLASTINE
    SEDLACEK, SM
    ONCOLOGY, 1993, 50 : 16 - 23
  • [28] Do body composition parameters correlate with response to targeted therapy in ER+/HER2-metastatic breast cancer patients? Role of sarcopenia and obesity
    Kripa, Endi
    Rizzo, Veronica
    Galati, Francesca
    Moffa, Giuliana
    Cicciarelli, Federica
    Catalano, Carlo
    Pediconi, Federica
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [29] Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2-Metastatic Breast Cancer
    Song, Yan
    Hao, Yanni
    Macalalad, Alexander R.
    Lin, Peggy L.
    Signorovitch, James E.
    Wu, Eric Q.
    BREAST CANCER-BASIC AND CLINICAL RESEARCH, 2015, 9 : 67 - 72
  • [30] Health-related quality of life and estimation of the minimally important difference in the Functional Assessment of Cancer Therapy-Endocrine Symptom score in postmenopausal ER+/HER2-metastatic breast cancer with low sensitivity to endocrine therapy
    Kikawa, Yuichiro
    Hagiwara, Yasuhiro
    Fujisawa, Tomomi
    Araki, Kazuhiro
    Iwamoto, Takayuki
    Sangai, Takafumi
    Shien, Tadahiko
    Takao, Shintaro
    Nishimura, Reiki
    Takahashi, Masato
    Toyama, Tatsuya
    Aihara, Tomohiko
    Mukai, Hirofumi
    Taira, Naruto
    PLOS ONE, 2022, 17 (11):
12345